Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 07 08 2020
accepted: 14 10 2020
entrez: 2 12 2020
pubmed: 3 12 2020
medline: 25 6 2021
Statut: epublish

Résumé

Antibodies are commonly used in organ transplant induction therapy and to treat autoimmune disorders. The effects of some biologics on the human immune system remain incompletely characterized and a deeper understanding of their mechanisms of action may provide useful insights for their clinical application. The goal of this study was to contrast the mechanistic properties of siplizumab with Alemtuzumab and rabbit Anti-Thymocyte Globulin (rATG). Mechanistic assay systems investigating antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell phagocytosis and complement-dependent cytotoxicity were used to characterize siplizumab. Further, functional effects of siplizumab, Alemuzumab, and rATG were investigated in allogeneic mixed lymphocyte reaction. Changes in T cell activation, T cell proliferation and frequency of naïve T cells, memory T cells and regulatory T cells induced by siplizumab, Alemtuzumab and rATG in allogeneic mixed lymphocyte reaction were assessed

Identifiants

pubmed: 33262770
doi: 10.3389/fimmu.2020.592553
pmc: PMC7686512
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antilymphocyte Serum 0
Antineoplastic Agents, Immunological 0
CD2 Antigens 0
FOXP3 protein, human 0
Forkhead Transcription Factors 0
Receptors, IgG 0
Alemtuzumab 3A189DH42V
Complement System Proteins 9007-36-7
thymoglobulin D7RD81HE4W
siplizumab KUW1QG1ZM3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

592553

Informations de copyright

Copyright © 2020 Binder, Sellberg, Cvetkovski, Berglund and Berglund.

Références

Am J Transplant. 2012 May;12(5):1079-90
pubmed: 22420320
Am J Transplant. 2020 Jan;20(1):88-100
pubmed: 31319439
Am J Transplant. 2011 Jan;11(1):22-33
pubmed: 21070604
Front Immunol. 2017 Feb 28;8:170
pubmed: 28293238
Drugs. 2014 Sep;74(14):1605-34
pubmed: 25164240
J Rheumatol. 1998 Aug;25(8):1457-61
pubmed: 9712083
N Engl J Med. 2006 Nov 9;355(19):1967-77
pubmed: 17093248
Clin Immunol. 2012 Jan;142(1):31-7
pubmed: 21555250
Transplantation. 1999 Nov 27;68(10):1588-96
pubmed: 10589960
Sci Rep. 2016 Oct 04;6:34382
pubmed: 27698437
Am J Transplant. 2005 Mar;5(3):465-74
pubmed: 15707400
Nat Med. 2009 Jul;15(7):746-9
pubmed: 19584865
Am J Transplant. 2017 Aug;17(8):2020-2032
pubmed: 28251801
Scand J Immunol. 2020 Jan;91(1):e12839
pubmed: 31630416
Toxins (Basel). 2014 Feb 28;6(3):869-91
pubmed: 24590384
Inflamm Allergy Drug Targets. 2009 Jul;8(3):236-46
pubmed: 19601884
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6175-80
pubmed: 11983909
Transplantation. 2000 Jun 27;69(12):2622-33
pubmed: 10910286
Ther Adv Neurol Disord. 2017 Oct;10(10):343-359
pubmed: 28966663
Cold Spring Harb Perspect Med. 2013 Dec 01;3(12):a015537
pubmed: 24296352
Immunology. 2009 Oct;128(2):260-70
pubmed: 19740383
Am J Transplant. 2013 Dec;13(12):3103-13
pubmed: 24168235
Am J Transplant. 2017 Jul;17(7):1713-1718
pubmed: 27888576
Clin Pharmacokinet. 2018 Feb;57(2):191-207
pubmed: 28669130
Transplantation. 2017 Jul;101(7):1587-1599
pubmed: 27653300
Immunol Cell Biol. 2003 Dec;81(6):487-95
pubmed: 14636246
Leukemia. 2007 Jul;21(7):1387-94
pubmed: 17410187
Immunobiology. 1992 Apr;184(4-5):359-71
pubmed: 1350565
J Immunol. 2006 Apr 15;176(8):4632-9
pubmed: 16585554
J Clin Invest. 2015 Aug 3;125(8):3285-96
pubmed: 26193635

Auteurs

Christian Binder (C)

Section of Clinical Immunology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Research and Development, ITB-Med AB, Stockholm, Sweden.

Felix Sellberg (F)

Section of Clinical Immunology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Research and Development, ITB-Med AB, Stockholm, Sweden.

Filip Cvetkovski (F)

Research and Development, ITB-Med AB, Stockholm, Sweden.

Erik Berglund (E)

Research and Development, ITB-Med AB, Stockholm, Sweden.
Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Transplantation Surgery, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.

David Berglund (D)

Section of Clinical Immunology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Research and Development, ITB-Med AB, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH